Farglitazar
From Wikipedia, the free encyclopedia
 |
|
|
Farglitazar
|
|
| Systematic (IUPAC) name | |
| N-(o-benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C34H30N2O5 |
| Mol. mass | 546.612 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Farglitazar is a is a peroxisome proliferator-activated receptor agonist which is being developed by GlaxoSmithKline for the treatment of hepatic fibrosis. It is currently in phase II clinical trials.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
